 
        | Report period | 2019 | 2020 | 2021 | 2022 | 2023 | Q2 24 | 
|---|---|---|---|---|---|---|
| End date of the reporting period |  |  |  |  |  |  | 
| Capitalization, $ |  |  |  |  |  |  | 
| Capitalization, $ |  |  |  |  |  |  | 
| Enterprise Value |  |  |  |  |  |  | 
| Book Value |  |  |  |  |  |  | 
| Shareholders Book Value |  |  |  |  |  |  | 
| Current liabilities |  |  |  |  |  |  | 
| Noncurrent liabilities |  |  |  |  |  |  | 
| Total liabilities |  |  |  |  |  |  | 
| Debt |  |  |  |  |  |  | 
| Cash and cash equivalents |  |  |  |  |  |  | 
| Net debt |  |  |  |  |  |  | 
| Assets |  |  |  |  |  |  | 
| Total ordinary shares |  |  |  |  |  |  | 
| Ordinary share price |  |  |  |  |  |  | 
| Ticker | Name | Type | Nominal value | ISIN | Price | 
|---|---|---|---|---|---|
| TECH:US | Bio-Techne | Common share | - | US09073M1045 | $76.42 | 
 investors.bio-techne.com
 investors.bio-techne.com investors.bio-techne.com
 investors.bio-techne.com investors.bio-techne.com
 investors.bio-techne.com investors.bio-techne.com
 investors.bio-techne.com| Company name | Bio-Techne | 
|---|---|
| Tags | #biotechnology, #s&p500 index | 
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology | 
| Business address | 614 McKinley Place NE Minneapolis, MN 55413 United States | 
| Mailing address | 614 McKinley Place NE Minneapolis, MN 55413 United States | 
| Website | investors.bio-techne.com | 
| Information disclosure | www.sec.gov | 
